This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.
RSA 318:51-b · Licensing of Limited Retail Drug Distributors Required
318:51-b Licensing of Limited Retail Drug Distributors Required. –
Copy linkNo person shall operate as a limited retail drug distributor, as defined in RSA 318:1, VII-a, without first having obtained a license to do so from the office of professional licensure and certification according to the eligibility requirements set forth in rule by the pharmacy board.
Copy linkNo license shall be issued under this section unless the applicant has furnished proof satisfactory to the board that:
Copy linkThe applicant is of good moral character or, if that applicant is an association or corporation, that the managing officers are of good moral character.
Copy linkThe applicant has sufficient space and security equipment as to properly carry on the business described in the application.
Copy linkThe license granted by this chapter shall at all times be displayed in a conspicuous place in the facility for which it is issued.
Copy linkThe applicant, other than a distributor of legend devices or medical gases, has a written contract with a pharmacist licensed in the state to serve as a consultant on all matters relating to the storage and dispensing of prescription drugs.
Copy linkNo license shall be granted to any person who has within 5 years been convicted of a violation of any law of the United States, or of any state, relating to drugs, as defined in this chapter or RSA 318-B, or to any person who is a drug-dependent person.
Copy linkAny person licensed pursuant to this section is subject to the provisions of RSA 318:29. Source. 2000, 271:5. 2007, 202:12, eff. Jan. 1, 2008. 2019, 264:11, eff. Sept. 17, 2019. 2023, 79:314, eff. Sept. 1, 2023.
Copy linkSource note
Source. 2000, 271:5. 2007, 202:12, eff. Jan. 1, 2008. 2019, 264:11, eff. Sept. 17, 2019. 2023, 79:314, eff. Sept. 1, 2023.
Source history
- 2000, 271:5
- 2007, 202:12, eff. Jan. 1, 2008
- 2019, 264:11, eff. Sept. 17, 2019
- 2023, 79:314, eff. Sept. 1, 2023
Related materials
Bill relationships
-
2026 HB1249
reference
rvices and Elderly Affairs ----------------------------------------------------------------- ANALYSIS This bill amends the definition of the practice of pharmacy under RSA 318 and authorizes pharmacists to prescribe certain prescription devices necessary for the appropriate delivery or administration of a prescribed drug. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
-
2026 HB1584
amend · effective 2027-01-01
each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons
-
2026 HB1584-FN
amend · effective 2027-01-01
each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons
-
2026 SB504
reference · effective 2027-01-01
including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin
-
2026 SB504-FN
reference · effective 2027-01-01
including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin
-
2026 SB665
amend · effective 2027-01-01
s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons
-
2026 SB665-FN
amend · effective 2027-01-01
s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons
-
2025 HB254
reference
ician licensed pursuant to RSA 329; (2) An osteopathic physician licensed pursuant to RSA 329; (3) An advanced practice registered nurse licensed pursuant to RSA 326-B; or (4) A pharmacist licensed pursuant to RSA 318; provided, however, that a pharmacist shall not qualify as an attending health care provider under RSA 137-M:1, II or as a consulting health care provider under RSA 137-M:1, III. (b) A "health care provider" d
-
2025 HB63
reference
may write a prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine for the postsecondary educational institution or independent school. IV. A pharmacist licensed under RSA 318 may dispense a valid prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine issued in the name of a postsecondary educational institution or an independent school. 200